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Vena Cava Filter Retrieval Rates and Factors Associated With
Retrieval in a Large US Cohort
Joshua D. Brown, PharmD, PhD; Driss Raissi, MD; Qiong Han, MD, PhD; Val R. Adams, PharmD; Jeffery C. Talbert, PhD
Background-—Retrieval of vena cava filters (VCFs) is important for safety as complications increase with longer dwell times. This
study assessed VCF retrieval rates and factors associated with retrieval in a national cohort.
Methods and Results-—VCFs were identified by procedural codes from an administrative claims database. Patients were identified
who had a VCF placement during a hospitalization from a national commercial administrative claims database. Indications for VCF
placement were identified as pulmonary embolism with or without deep vein thrombosis, deep vein thrombosis only, or
prophylactic. Patient demographic and clinical characteristics were included in proportional hazard regression models to find
associations with early (90-day) and 1-year VCF retrieval. Initiation of anticoagulation and the correlation between time-to-retrieval
and time-to-initiation of anticoagulation were observed. Of 54 766 patients receiving a VCF, 36.9% had pulmonary embolism,
43.9% had deep vein thrombosis only, and 19.2% had no apparent venous thromboembolism present. Over the 1 year of follow-up,
the cumulative incidence of VCF retrieval was 18.4%. Retrieval increased over time from a low of 14.0% in 2010 up to 24% in
2014. In adjusted time-to-event models, increasing age, differing regions, and some comorbidities were associated with poorer
retrieval rates. Initiation of anticoagulation was poorly correlated with retrieval, with anticoagulation preceding retrieval by a
median of 51 days while those without retrieval had a median of 278 days of exposure to anticoagulation.
Conclusions-—VCF retrieval increased over the study period but remained suboptimal and was weakly correlated with
anticoagulation initiation. ( J Am Heart Assoc. 2017;6:e006708. DOI: 10.1161/JAHA.117.006708.)
Key Words: pulmonary embolism • retrieval device • vena cava • vena cava filter • venous thromboembolism
V ena cava filters (VCFs) are used to mechanically preventthrombi from migrating to the pulmonary circulation.
Generally, VCFs are reserved for patients who have absolute
or relative contraindications to anticoagulation and who are at
a high risk of recurrent venous thromboembolism (VTE).1–3
With the advent of retrievable VCFs, there has been a marked
increase in overall use.4–6 Retrievable VCFs differ in that they
can be removed once contraindications have subsided and
patients can be initiated on anticoagulation.
In real-world settings, retrieval rates of VCFs have been
dismal, with reports ranging from 10% to 50% and an estimated
average near 30%.7,8 Poor retrieval rates correspond to an
increase in reported adverse events.7 Complications associ-
ated with VCFs include increased risk of deep vein thrombosis
(DVT), inferior vena cava thrombosis, inferior vena cava
penetration, VCF fracture, and VCF embolization.7,9–11 Given
these trends, the US Food and Drug Administration has issued a
safety communication highlighting the need to remove VCFs
once the risk of pulmonary embolism (PE) has subsided based
on modeling studies showing that VCFs are most clinically
beneficial if retrieved within 90 days after implantation.11,12
Given the continued growth in VCF use and the variation
that has been observed between institutions,13–17 assess-
ment of what factors drive retrieval rates and timing of
anticoagulation on a national scale is needed to evaluate
clinical practice.18 This study sought to evaluate the trend in
retrieval rates and patient factors associated with retrieval as
well as the association between retrieval and anticoagulation.
While retrieval rates were expected to increase over time, we
hypothesized differential retrieval based on indication and
patient characteristics. Furthermore, we hypothesized there
would be a weak association between retrieval and anticoag-
ulation, although treatment with anticoagulation generally
indicates there would no longer be a continued need for an
indwelling VCF.
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This observational cohort study utilized the Truven Health
Analytics MarketScan database, which are administrative
healthcare claims data including medical diagnostic and
procedural information and pharmacy fill records billed to an
individual’s health insurance. The data include information for
40 million unique individuals per year. The university’s
Institutional Review Board approved use of the data and
waived the requirement for informed consent of participants
given that the data are de-identified and collected for
nonresearch purposes.
Cohort Identification
All patients during the years 2010 to 2014 who had a VCF
placed were identified using Current Procedural Terminology
(CPT: 37191, 37620, 35940) and International Classification
of Diseases, 9th revision (ICD-9: 38.7) procedural codes. The
indication for VCF was identified by ICD-9 diagnosis codes as
PE (415.1x) with or without DVT, DVT only (451.xx or 453.xx),
or no apparent VTE (prophylactic).19,20 To increase the validity
of these indication diagnoses, only the primary diagnosis field
was used. For inclusion, patients were required to be 18 years
old or older and have a minimum of 6 months of eligibility in
the database before VCF placement.
Cohort Characteristics
Demographic variables included age, sex, geographic region,
and residence status. Age was divided into 18 to 34, 35 to 44,
45 to 54, 55 to 64, 65 to 74, and 75 and older categories.
Geographic region included US census regions (Northeast,
North Central, South, West, and unknown) and residence
status was divided into urban or rural. Insurance status was
classified as commercial or Medicare, fully or partially
capitated, and assignment to a primary care provider (PCP).
Conditions and procedures present during VCF implanta-
tion were recorded. Concurrent bleeding, unstable condition,
sepsis or septic shock, infection, anemia, trauma, and
pregnancy were all recorded using ICD-9 diagnosis codes.13,20
Patients receiving thrombolytic therapy, embolectomy proce-
dures, or major surgery were identified using a combination of
procedural codes.21 Patients who died during the hospitaliza-
tion during which the VCF was placed were also noted.
Comorbid conditions observed in the pre-index period
consisted of Charlson comorbidities along with a Charlson
Comorbidity Index, which represents the overall “comorbidity
burden” widely used for risk adjustment.22,23
Outcome Events
The primary outcome was VCF retrieval identified by CPT
(37 193, 37 203) and ICD-9 (38.7) procedure codes. Given
that the ICD-9 procedure code for placement and retrieval is
the same, retrievals for those patients only having the ICD-9
procedure code present had to be on separate days to record
retrieval. However, since CPT codes and not ICD-9 codes are
used for billing purposes, patients lacking the CPT codes were
the exception, with >95% of all patients having CPT codes
recorded. Patients were followed forward from the VCF
placement until the VCF was retrieved, they died, they were
lost to follow-up, or the end of the study period. The 30-, 60-,
90-, 180-day, and 1-year cumulative incidence of VCF retrieval
was estimated using Fine and Gray’s time-to-event, survival
analysis methodology, accounting for death as a competing
risk.24 Time to VCF retrieval was also reported.
Time to Anticoagulation Initiation
Anticoagulation initiation was assessed as the first outpatient
prescription for an injectable (dalteparin, enoxaparin,
Clinical Perspective
What Is New?
• This is the first known study to examine retrieval rates for
vena cava filters (VCFs) in a national cohort.
• The results are consistent with prior meta-analyses of single
institution retrieval rates showing about a 25% to 30%
retrieval rate of all placed.
• Despite safety warnings for indwelling VCFs, most remained
in place and were poorly correlated with initiation of
anticoagulation.
• Retrieval rates were strongly dependent on age, with older
patients less likely to have retrieval, patient residence,
prophylactic indication for VCF placement (no thrombosis
present), and having VCF placement in more recent years.
What Are the Clinical Implications?
• The US Food and Drug Administration has suggested that
VCFs be removed once clinically appropriate to avoid
complications.
• These warnings were in response to many reports of VCF
failures including device fractures and penetration of the
vena cava that were associated with indwell time.
• In order to maximize the net clinical benefit of VCFs,
patients should be initiated on anticoagulation once
contraindications have abated and VCFs should be removed.
• Utilization of VCFs and subsequent retrieval rates vary
widely by geography, suggesting that institutions and clinics
should evaluate their practices to better ensure patient
safety.
DOI: 10.1161/JAHA.117.006708 Journal of the American Heart Association 2






















tinzaparin, fondaparinux) or oral (warfarin, dabigatran, rivarox-
aban, apixaban) anticoagulant. Those with prophylactic indi-
cations (“no VTE”) were excluded as they might not have
indications for anticoagulation on discharge. Furthermore,
those who had VCF retrieval before discharge were excluded.
Time to anticoagulation was compared with the time to
retrieval and described for those who did not have retrieval
during follow-up. Time for both events was calculated based
on the date of discharge from a hospitalization since the filled
prescriptions data would not be available until hospital
discharge occurred.
Time-to-Event Analysis
To identify factors associated with VCF retrieval, we devel-
oped a Cox proportional hazards model including patient
characteristics. The proportionality assumption for all vari-
ables was evaluated for using Schoenfeld residuals as well as
using time as an interaction term for each variable. Both
methods showed that this assumption held true. Because of
collinearity with age, Medicare or commercial insurance
status was excluded in the model. Two models were
estimated predicting 90-day and 1-year retrieval. The 90-day
time point was chosen to represent “early retrievals” and was
consistent with a prior modeling study showing higher net
clinical benefit if removed in <90 days.11 Patients who had
not had retrieval or had not died at the end of the 90-day or
365-day period were censored. Hazard ratios and their 95%
confidence intervals were estimated. All analyses were
conducted using SAS Enterprise Guide version 7.1 (Cary,




During 2010 to 2014, 54 766 patients received a VCF and
met the eligibility requirements to be included in the study. Of
these, 36.9% presented with a PE, 43.9% with DVT alone, and
19.2% had no apparent VTE present (Table 1). The mean (SD)
age of the cohort was 65 (16) years old, 51% were female, and
they were geographically diverse with nearly 85% residing in
urban areas. Insurance details included 13.9% of the cohort
having a primary care provider and 8.6% having insurance with
full or partial capitated payments. A total of 1628 (3.0%) of
the cohort died during the initial hospitalization and were not
included in subsequent analyses.
Overall, 14.3% (N=7619) of the cohort who survived the
index hospitalization had the VCF retrieved within 1 year
and 8% (N=4228) died (Table 2). For those who had
retrieval, the mean (SD) time to retrieval was 93 (78) days,
with a median of 71 days and interquartile range (IQR) of
35 to 130 days. Those with PE had the highest mean and
median times to retrieval (101 and 81 days) compared with
those with DVT only (91 and 68 days) and compared with
those with no VTE (83 and 61 days, P<0.001 for all
comparisons).
Figure 1 shows the cumulative incidence of VCF retrieval
by the index indication and Table 3 shows the cumulative
incidence for selected variables. At 1 year, retrieval was
highest for those with no VTE on index, reaching nearly
25% (23.9–25.8%). Retrieval increased with each year of
study, going from 14.0% (13.3–14.7%) in 2010 up to 38.2%
(19.4–57.0%, skewed by low follow-up time) in 2014
(P<0.001 for trend excluding 2014 data). Data from 2014
allowed for smaller sample size for 1-year of follow-up.
However, trends were consistent across smaller time
frames for 2014 and showed a year-over-year increase in
retrieval at all time points. Differences in retrieval between
age groups were significant, with younger age groups
having higher retrieval. For example, those aged 18 to 34
had 1-year retrieval of 42.8% (40.4–45.2%) while retrieval in
those 75 years old and older was just 5.4% (5.0–5.8%,
P<0.001).
Factors Related to Retrieval
In fully adjusted analyses (Table 4), age remained signifi-
cantly associated with VCF retrieval at both 90 days and
365 days of follow-up, although the association was much
stronger for the 1-year model. Patients with no VTE were
more likely to have retrieval compared with those with DVT
only, and there was no difference in retrieval between
those with PE compared with those with DVT. Geographic
region was also significant, with those residing in the North
Central (90 days and 1 year) and West (1 year only) regions
being more likely to have retrieval compared with those in
the Northeast.
Year of filter placement was modeled both as a covariate
as well as used to stratify the analysis. In stratified analysis,
no differences were observed between the covariates and
their association with VCF retrieval compared with the base
model with year as a covariate. As a covariate, each year of
VCF placement was associated with increased 90-day and
1-year retrieval compared with year 2010. For the final year
2014, this corresponded to nearly a 2-fold difference in
retrieval rate compared with 2010 (hazard ratio=1.90, 95%
confidence interval, 1.76–2.06).
Time to Anticoagulation
During follow-up, the data set had follow-up prescription
information for 37 272 persons in the cohort with DVT/PE
DOI: 10.1161/JAHA.117.006708 Journal of the American Heart Association 3






















Table 1. Demographic and Clinical Characteristics of Patients Receiving VCFs by Indication
All Pulmonary Embolism Deep Vein Thrombosis No PE/DVT
N % N % N % N %
54 766 100.0 20 202 36.9 24 060 43.9 10 504 19.2
Age group (y)
Mean, SD 65 (16) 64 (15) 69 (16) 60 (17)
18 to 34 2196 4.0 728 3.6 610 2.5 858 8.2
35 to 44 3551 6.5 1347 6.7 1183 4.9 1021 9.7
45 to 54 7888 14.4 3337 16.5 2757 11.5 1794 17.1
55 to 64 13 076 23.9 5530 27.4 4881 20.3 2665 25.4
65 to 74 9422 17.2 3452 17.1 4334 18.0 1636 15.6
75 and older 17 846 32.6 5492 27.2 10 038 41.7 2316 22.0
Sex of patient
Male 26 839 49.0 10 217 50.6 11 542 48.0 5080 48.4
Female 27 927 51.0 9985 49.4 12 518 52.0 5424 51.6
Region
Northeast 11 526 21.0 4154 20.6 5191 21.6 2181 20.8
North Central 15 678 28.6 5752 28.5 7142 29.7 2784 26.5
South 18 448 33.7 6666 33.0 7882 32.8 3900 37.1
West 7891 14.4 3158 15.6 3361 14.0 1372 13.1
Unknown 1223 2.2 472 2.3 484 2.0 267 2.5
Residence
Rural 8496 15.5 3119 15.4 3381 14.1 1996 19.0
Urban 46 270 84.5 17 083 84.6 20 679 85.9 8508 81.0
Concurrent conditions during hospitalization
Bleed 5004 9.1 1418 7.0 2779 11.6 807 7.7
Unstable condition 870 1.6 243 1.2 464 1.9 163 1.6
Sepsis 2351 4.3 619 3.1 1360 5.7 372 3.5
Infection 9202 16.8 3105 15.4 4680 19.5 1417 13.5
Anemia 10 195 18.6 3193 15.8 5433 22.6 1569 14.9
Trauma 5777 10.5 1600 7.9 3027 12.6 1150 10.9
Thrombolytic therapy 841 1.5 452 2.2 316 1.3 73 0.7
Embolectomy procedure 367 0.7 176 0.9 149 0.6 42 0.4
Major surgery 13 371 24.4 5249 26.0 5836 24.3 2286 21.8
Pregnant 441 0.8 148 0.7 221 0.9 72 0.7
Died during hospitalization 1628 3.0 720 3.6 461 1.9 447 4.3
Comorbid conditions
CCI score, mean (SD) 3.1 (3.3) 2.9 (3.3) 3.5 (3.4) 2.9 (3.3)
History of VTE 4864 8.9 1522 7.5 2149 8.9 1193 11.4
History of bleeding 8483 15.5 2587 12.8 4577 19.0 1319 12.6
MI 3254 5.9 1122 5.6 1623 6.7 509 4.8
CHF 8464 15.5 2620 13.0 4514 18.8 1330 12.7
PVD 7450 13.6 2147 10.6 4030 16.7 1273 12.1
Dementia 2366 4.3 621 3.1 1518 6.3 227 2.2
Continued
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indications and who did not have retrieval before discharge.
Among these, 23 510 (63.1%) initiated anticoagulation
including 61% who never had retrieval, 79.2% among those
with retrieval, and 47.8% among those who died, with
median time to initiation of 17 (IQR 6–50) days. Initiation
of anticoagulation differed significantly for those who
eventually had retrieval (N=4729, median 11, IQR 5–-
31 days) and those who did not have retrieval (N=17 628,
median 17, IQR 6–50 days, P<0.001). Overall, time to
anticoagulation and time to retrieval were poorly correlated,
with anticoagulation preceding retrieval by a median of 51
(IQR 13–110) days and R2=0.06 (Figure 2). For those who
never had retrieval, there was a median of 278 (IQR 98–
350) days of anticoagulation treatment during the 1-year
follow-up period.
Discussion
In PREPIC2 (Prevention du Risque d’Embolie Pulmonaire par
Interruption Cave 2), the only randomized trial for retrievable
VCFs, the retrieval rate was >90% with a dedicated 3-month
follow-up visit.25 However, in real-world practice, estimates of
the retrieval rates range much lower, with an average of about
one third of all VCFs eventually being retrieved.7 Patients are
at risk for complications including inferior vena cava throm-
bosis, device fracture, device migration, and DVT so long as
Table 1. Continued
All Pulmonary Embolism Deep Vein Thrombosis No PE/DVT
N % N % N % N %
COPD 12 925 23.6 4872 24.1 5735 23.8 2318 22.1
Rheumatism 2286 4.2 801 4.0 1087 4.5 398 3.8
PUD 1593 2.9 503 2.5 829 3.4 261 2.5
Mild liver disease 4344 7.9 1586 7.9 1958 8.1 800 7.6
Severe liver disease 549 1.0 135 0.7 315 1.3 99 0.9
Diabetes mellitus 13 623 24.9 4483 22.2 6322 26.3 2818 26.8
Diabetes mellitus w/complications 3663 6.7 1040 5.1 1853 7.7 770 7.3
Paralysis 2244 4.1 672 3.3 1228 5.1 344 3.3
Renal disease 6684 12.2 1713 8.5 3836 15.9 1135 10.8
Cancer 16 672 30.4 6251 30.9 7856 32.7 2565 24.4
Metastatic cancer 7534 13.8 3013 14.9 3433 14.3 1088 10.4
Stroke 9744 17.8 2957 14.6 5240 21.8 1547 14.7
Hypertension 30 918 56.5 10 719 53.1 14 541 60.4 5658 53.9
CHD 11 125 20.3 3604 17.8 5597 23.3 1924 18.3
Hyperlipidemia 18 195 33.2 6676 33.0 8047 33.4 3472 33.1
Insurance source
Commercial 26 350 48.1 10 821 53.6 9281 38.6 6248 59.5
Medicare 28 416 51.9 9381 46.4 14 779 61.4 4256 40.5
Insurance details
Assigned care provider 7586 13.9 2910 14.4 3116 13.0 1560 14.9
Capitated payment 4718 8.6 1821 9.0 1969 8.2 928 8.8
Year VCF placed
2010 11 784 21.5 4250 21.0 5239 21.8 2295 21.8
2011 12 750 23.3 4565 22.6 5672 23.6 2513 23.9
2012 12 210 22.3 4369 21.6 5393 22.4 2448 23.3
2013 9395 17.2 3596 17.8 4062 16.9 1737 16.5
2014 8627 15.8 3422 16.9 3694 15.4 1511 14.4
CCI indicates Charlson Comorbidity Index; CHD, coronary heart disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DVT, deep vein thrombosis; IVC,
inferior vena cava; MI, myocardial infarction; PE, pulmonary embolism; PUD, peptic ulcer disease; PVD, peripheral vascular disease; VCF, vena cava filter; VTE, venous thromboembolism
DOI: 10.1161/JAHA.117.006708 Journal of the American Heart Association 5






















the VCF remains in place.7,26 One study found that there is an
optimal net clinical benefit if a VCF is retrieved within 29 to
54 days after placement in prophylactic indications, which
remained in favor of VCFs up to 180 days postimplantation.11
That article was referenced by a US Food and Drug
Administration safety communication, which responded to
multiple reports of complications with VCFs and increasing
publicity through litigation and media.12
The current analysis is consistent with other reports
regarding VCF retrieval.7,8 The retrieval rate increased over
time, from roughly every 1-out-7 VCFs being retrieved in 2010
up to 1-out-4 retrieved in 2014. This effect may be explained
by the increased attention VCFs received over this time period
including US Food and Drug Administration safety alerts, as
well as guideline updates (American College of Chest
Physicians),1 which called for more conservative use of VCFs
Table 2. Outcomes of Patients Receiving VCFs At 1 Year of Follow-Up
Overall PE DVT No VTE
Outcome
VCF retrieval 7619 (14.3%) 2884 (14.8%) 2686 (11.4%) 2049 (20.4%)
Died 4228 (8.0%) 1627 (8.4%) 1950 (8.3%) 651 (6.5%)
Censored 41 291 (77.7%) 14 971 (76.8%) 18 963 (80.4%) 7357 (73.2%)
Follow-up time
Mean, SD 202 (144) 202 (143) 202 (145) 200 (144)
Median, IQR 186 (56–365) 188 (58–365) 187 (54–365) 176 (56–365)
Time to retrieval
Mean, SD 93 (78) 101 (81) 91 (79) 83 (73)
Median, IQR 71 (35–130) 81 (38–143) 68 (33–132) 61 (32–113)
Time to death
Mean, SD 96 (91) 94 (91) 97 (91) 100 (90)
Median, IQR 63 (26–142) 58 (24–140) 66 (26–144) 67 (32–141)
DVT indicates deep vein thrombosis; IQR, interquartile range; PE, pulmonary embolism; VCF, vena cava filter; VTE, venous thromboembolism.
Figure 1. Cumulative incidence of vena cava filter (VCF) retrieval by indication over 1-y of follow-up
accounting for death as a competing risk. VTE indicates venous thromboembolism.
DOI: 10.1161/JAHA.117.006708 Journal of the American Heart Association 6






















compared with guidelines presented by other physician
societies in interventional radiology and trauma.27,28 For
those who did have their VCF retrieved in our study, time to
retrieval was within mean and median times of 93 and 71
days postimplantation. However, retrieval was poorly corre-
lated with anticoagulation initiation.
Several patient-related factors were also associated with
retrieval, including demographic and clinical characteristics.
Increasing age of the patient was associated with lower
retrieval, which likely contributed to perceived ongoing risk of
PE or a desire to not treat older individuals with anticoagu-
lation. Region of residence was also strongly associated with
retrieval, which may indicate regional practice differences as
well as differences in patient demography. Patients living in an
urban setting were more likely to have their filter retrieved as
well, suggesting that patients being referred to a distant
medical center for VCF placement may have limited follow-up
for retrieval. Among patient comorbidities, those considered
prothrombotic (eg, cancer, stroke, hyperlipidemia, myocardial
infarction) and related to bleeding (eg, liver disease) were
associated with lower retrieval.
Other studies investigating factors associated with retrieval
rates have focused on poor patient follow-up as the primary
reason VCFs are not removed.29–33 Patient follow-up is
generally left to the referring or primary physician, with some
studies showing improved retrieval if the responsibility of
follow-up is placed on the implanting physician instead.32–34 In
institutions where the implanting physicians are made respon-
sible for patient follow-up, retrieval rates have increased from
24% to 59% and 29% to 60%.32,33
While there is inherent concern for patient safety associ-
ated with these low retrieval rates, clinical practices are also
financially incentivized to increase retrieval of VCFs. One
study showed that because of the increased cost between
Table 3. Cumulative Incidence and 95% Confidence Interval of Inferior VCF Retrieval at Time Intervals by Key Demographic and
Clinical Factors
30 Days 60 Days 90 Days 180 Days 365 days
Overall, % 3.3 (3.1–3.5) 6.9 (6.7–7.2) 9.8 (9.5–10.1) 14.9 (14.6–15.2) 18.4 (18.0–18.8)
Indication
No VTE, % 5.2 (4.7–5.6) 11.0 (10.4–11.7) 15.0 (14.3–15.8) 21.3 (20.4–22.2) 24.8 (23.9–25.8)
DVT, % 2.8 (2.6–3.0) 5.8 (5.5–6.1) 7.9 (7.5–8.2) 12.1 (11.6–12.6) 14.9 (14.3–15.4)
PE, % 2.9 (2.7–3.1) 6.1 (5.8–6.5) 9.3 (8.9–9.8) 14.8 (14.3–15.4) 19.2 (18.5–19.8)
Year VCF placed
2010, % 3.1 (2.8–3.5) 6.0 (5.6–6.5) 8.0 (7.5–8.6) 11.3 (10.7–11.9) 14.0 (13.3–14.7)
2011, % 3.0 (2.7–3.3) 6.3 (5.9–6.8) 8.8 (8.3–9.3) 13.2 (12.6–13.9) 16.1 (15.4–16.8)
2012, % 3.4 (3.1–3.8) 7.5 (7.0–8.0) 9.9 (9.4–10.5) 15.6 (14.9–16.3) 19.2 (18.4–20.0)
2013, % 3.3 (3.0–3.7) 7.5 (7.0–8.1) 11.2 (10.5–11.9) 17.1 (16.3–18.0) 21.6 (20.7–22.6)
2014, % 3.7 (3.3–4.2) 7.7 (7.1–8.3) 12.4 (11.6–13.3) 20.5 (19.4–21.6) 38.2 (19.4–57.0)*
Age group (y)
18 to 34, % 6.8 (5.8–7.9) 15.2 (13.7–16.8) 22.8 (21.0–24.7) 34.9 (32.7–37.1) 42.8 (40.4–45.2)
35 to 44, % 6.1 (5.3–6.9) 13.9 (12.7–15.1) 18.9 (17.6–20.3) 28.4 (26.8–30.0) 35.5 (33.7–37.2)
45 to 54, % 4.9 (4.5–5.5) 11.4 (10.7–12.2) 15.9 (15.0–16.8) 23.7 (22.6–24.7) 29.3 (28.1–30.4)
55 to 64, % 3.9 (3.5–4.2) 8.0 (7.5–8.5) 11.5 (10.9–12.1) 17.8 (17.0–18.5) 21.8 (21.0–22.7)
65 to 74, % 2.7 (2.4–3.1) 5.3 (4.8–5.8) 7.4 (6.9–8.0) 11.4 (10.7–12.1) 14.1 (13.3–15.0)
75 and older, % 1.4 (1.2–1.6) 2.4 (2.1–2.6) 3.1 (2.8–3.3) 4.5 (4.1–4.8) 5.4 (5.0–5.8)
Cancer
Yes, % 2.6 (2.3–2.8) 4.5 (4.2–4.9) 6.3 (5.9–6.7) 9.1 (8.6–9.7) 11.7 (11.1–12.4)
No, % 3.6 (3.4–3.8) 7.9 (7.6–8.2) 11.1 (10.8–11.5) 17.0 (16.6–17.5) 20.8 (20.4–21.3)
Insurance source
Commercial, % 4.8 (4.5–5.0) 10.5 (10.1–10.9) 14.9 (14.5–15.4) 22.6 (22.1–23.2) 28.0 (27.4–28.6)
Medicare, % 1.9 (1.7–2.0) 3.4 (3.2–3.6) 4.6 (4.3–4.9) 7.0 (6.6–7.3) 8.6 (8.2–8.9)
DVT indicates deep vein thrombosis; VCF, vena cava filter; PE, pulmonary embolism; VTE, venous thromboembolism.
*Estimates for long-term follow-up in 2014 are unstable because of smaller sample sizes. Extrapolation of 2014 6-month estimates with the overall trend in retrieval rates across 2010 to
2014 produce a retrieval estimate of 23% to 25%.
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Table 4. Regression Results Showing Patient Factors Associated With 90-D (Early) Retrieval and 1-Year Retrieval
90-D Retrieval 1-Y Retrieval
HR 95% CI HR 95% CI
Age group (y)
18 to 34 Ref. Ref. Ref. Ref. Ref. Ref.
35 to 44 0.97 0.94 1.00 0.88 0.80 0.97
45 to 54 0.95 0.92 0.98 0.79 0.72 0.86
55 to 64 0.91 0.88 0.93 0.62 0.57 0.68
65 to 74 0.87 0.84 0.89 0.41 0.37 0.45
75 and older 0.82 0.80 0.84 0.17 0.15 0.19
Sex
Male Ref. Ref. Ref. Ref. Ref. Ref.
Female 1.01 1.01 1.02 1.04 0.99 1.09
Region
Northeast Ref. Ref. Ref. Ref. Ref. Ref.
North Central 1.03 1.02 1.04 1.29 1.20 1.38
South 0.99 0.98 1.00 0.89 0.83 0.95
West 1.10 1.09 1.12 1.89 1.76 2.04
Unknown 1.01 0.98 1.04 1.24 1.05 1.46
Residence
Rural Ref. Ref. Ref. Ref. Ref. Ref.
Urban 1.01 1.00 1.02 1.13 1.06 1.21
Index VTE
DVT only Ref. Ref. Ref. Ref. Ref. Ref.
No VTE 1.05 1.03 1.06 1.24 1.17 1.32
PE 0.99 0.98 1.00 0.99 0.93 1.04
Concurrent conditions during hospitalization
Bleed 1.00 0.99 1.02 1.10 0.93 1.29
Unstable condition 0.98 0.96 1.00 0.80 0.60 1.06
Sepsis 1.00 0.98 1.01 0.92 0.76 1.12
Infection 0.98 0.97 0.99 0.84 0.76 0.91
Anemia 0.99 0.98 0.99 0.91 0.84 0.98
Trauma 0.99 0.98 1.00 1.00 0.92 1.09
Thrombolytic therapy 1.06 1.02 1.09 1.29 1.11 1.49
Embolectomy procedure 1.00 0.96 1.04 0.89 0.68 1.17
Major surgery 0.98 0.97 0.99 0.92 0.87 0.97
Pregnant 1.05 0.99 1.11 1.36 1.15 1.60
Comorbid conditions during pre-index look back
CCI score (per 1 unit) 1.00 0.99 1.01 0.97 0.90 1.05
History of VTE 1.03 1.02 1.04 1.17 1.08 1.26
History of bleeding 0.98 0.97 0.99 0.77 0.67 0.87
Myocardial infarction 0.99 0.98 1.00 0.82 0.71 0.96
Heart failure 0.98 0.97 0.99 0.67 0.60 0.74
Peripheral vascular disease 0.99 0.98 1.00 0.85 0.77 0.94
Continued
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retrievable and permanent devices, retrievable devices are
only cost-effective in interventional radiology clinics if at least
40% are eventually retrieved, driven by separate billable
procedure codes for implantation and retrieval.34 Even
without the cost differential between permanent and retriev-
able devices, it is inherent that clinic revenue will be increased
with improved patient follow-up, management, and retrieval.
At least 1 study at a single institution evaluated the financial
feasibility of implementing a quality improvement initiative
within their clinical practice.35 They compared baseline
retrieval rates with those achieved by issuing letters to
patients and then with those achieved with prospective
follow-up of patients. Overall, their retrieval rates increased
from 8% to 40% with mailed letters to retrospective patients,
and increased further up to 52% with prospective follow-up of
new patients. Although improving VCF retrieval requires a
shift in patient management, retrieval will improve patient
outcomes and provides financial incentive to the clinic.
Limitations
This study has limitations inherent to all studies utilizing
administrative claims data.36,37 Most notably, detailed clin-
ical data are not available, which may have impacted the
study results. Procedural codes were utilized to identify VCF
placement; however, these codes are not specific to
permanent or retrievable devices. As of 2006, retrievable
devices made up about 85% of the VCF market in the United
States, which likely increased to >90% since then.38–41
Therefore, the retrieval estimates presented here are under-
estimated. Assuming that 10% to 20% of all VCFs used are
permanent and thus cannot be retrieved, this would make
Table 4. Continued
90-D Retrieval 1-Y Retrieval
HR 95% CI HR 95% CI
Dementia 0.97 0.96 0.98 0.31 0.22 0.43
COPD 0.99 0.98 1.00 0.88 0.83 0.94
Rheumatism 1.00 0.98 1.01 0.96 0.84 1.08
Peptic ulcer disease 1.02 1.00 1.04 1.16 0.95 1.41
Mild liver disease 1.00 0.98 1.01 1.00 0.91 1.11
Severe liver disease 0.99 0.98 1.00 0.86 0.81 0.92
Diabetes mellitus 0.99 0.98 1.00 0.96 0.85 1.09
Diabetes mellitus w/complications 0.98 0.97 1.00 0.76 0.65 0.89
Paralysis 0.98 0.97 0.99 0.81 0.73 0.90
Renal disease 0.99 0.98 1.00 0.94 0.87 1.00
Cancer 0.91 0.89 0.94 0.28 0.17 0.46
Metastatic cancer 0.92 0.90 0.93 0.43 0.38 0.49
Stroke 0.98 0.98 0.99 0.80 0.73 0.88
Hypertension 1.00 0.99 1.00 0.95 0.90 0.99
Coronary heart disease 1.00 0.99 1.00 0.87 0.80 0.94
Hyperlipidemia 1.02 1.01 1.03 1.23 1.17 1.30
Insurance details
Assigned care provider 1.00 0.99 1.02 1.03 0.94 1.12
Capitated payment 0.99 0.97 1.00 0.84 0.75 0.94
Year VCF placed
2010 Ref. Ref. Ref. Ref. Ref. Ref.
2011 1.01 1.00 1.02 1.19 1.11 1.28
2012 1.03 1.02 1.04 1.41 1.32 1.52
2013 1.04 1.03 1.05 1.63 1.51 1.75
2014 1.05 1.04 1.07 1.90 1.76 2.06
C-index for models: 90-d retrieval (0.695), 1-y retrieval (0.720). CCI indicates Charlson Comorbidity Index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; DVT, deep
vein thrombosis; HR, hazard ratio; PE, pulmonary embolism; VTE, venous thromboembolism.
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our estimated retrieval 26% to 30%, making this corrected
estimate near previous estimates of national retrieval rates
of 30%.6,7
We allowed enrollment of patients in 2014, but those
enrolled later in 2014 would have limited follow-up, which
skewed the estimates of cumulative retrieval at 365 days.
However, the increasing trend in retrieval rates is stable
across estimates at earlier time points (30, 60, 90, and
180 days) in 2014. Extrapolating these stable estimates from
180 days to 365 days across all years shows a trend
increasing year-to-year of +2% to 4%. Therefore, we have
estimated that with perfect follow-up for those enrolled in
2014, the retrieval estimate would be nearer 23% to 25%.
It is unclear how selection of retrievable versus permanent
devices would differ between, for example, older versus
younger patients or in cancer patients with poor prognosis,
adding some uncertainty to the comparison of retrieval
between certain relevant groups. However, in contemporary
patients, use of retrievable VCFs (also referred to as
“optional” VCFs because they can be left permanently or
retrieved when clinically indicated) may be a more preferred
therapeutic option allowing for flexibility in care versus
nonretrievable alternatives. Thus, while there may be a
differential influence of this limitation, the results are still
interpretable to identify patient subgroups that are less likely
to receive, as well as to not have retrieval of, retrievable VCFs.
Therefore, the trend showing an increase in retrieval rates
likely indicates both a trend in uptake of retrievable VCFs as
well as increased retrieval rates. More work will be needed
with detailed clinical data to determine differences in
selection of permanent versus retrievable treatment options.
Lastly, routine medications administered during a hospital
stay are often omitted from billing records because of
capitated payment systems. Thus, we did not attempt to
observe use of anticoagulation during the hospital stay
because it would be unreliably reported or unreported.
Conclusion
In this national study of VCF retrieval, less than 1 of every 4
filters was retrieved within 1 year. Retrieval rates differ based
on patient characteristics but increased over the study time
period (2010–2014), while retrieval and initiation of antico-
agulation were poorly correlated. Physicians should consider
ongoing indications for indwelling VCFs and timing of retrieval
with anticoagulation initiation throughout follow-up to opti-
mize patient care.
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solely the responsibility of the authors and does not neces-
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Figure 2. Plot of times to outpatient anticoagulation and vena cava filter retrieval. Black line represents
the fit of the data. Time is based on follow-up after the discharge date from the hospitalization where the
VCF was placed. Those with prophylactic indications and those with retrieval before discharge are excluded.
R2=0.06. VCF indicates vena cava filter.
DOI: 10.1161/JAHA.117.006708 Journal of the American Heart Association 10



























1. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M,
King CS, Morris TA, Sood N. Antithrombotic Therapy for VTE disease. Chest.
2016;149:315–352.
2. Kaufman JA, Kinney TB, Streiff MB, Sing RF, Proctor MC, Becker D, Cipolle M,
Comerota AJ, Millward SF, Rogers FB. Guidelines for the use of retrievable and
convertible vena cava filters: report from the Society of Interventional
Radiology multidisciplinary consensus conference. J Vasc Interv Radiol.
2006;17:449–459.
3. Kaufman JA, Rundback JH, Kee ST, Geerts W, Gillespie D, Kahn SR, Kearon C,
Rectenwald J, Rogers FB, Stavropoulos SW. Development of a research agenda
for inferior vena cava filters: proceedings from a multidisciplinary research
consensus panel. J Vasc Interv Radiol. 2009;20:697–707.
4. Stein PD, Kayali F, Olson RE. Twenty-one-year trends in the use of inferior vena
cava filters. Arch Intern Med. 2004;164:1541–1545.
5. Stein PD, Matta F, Hull RD. Increasing use of vena cava filters for prevention of
pulmonary embolism. Am J Med. 2011;124:655–661.
6. Desai SS, Naddaf A, Pan J, Hood D, Hodgson KJ. Impact of consensus
statements and reimbursement on vena cava filter utilization. J Vasc Surg.
2016;64:425–429.
7. Angel LF, Tapson V, Galgon RE, Restrepo MI, Kaufman J. Systematic review of
the use of retrievable inferior vena cava filters. J Vasc Interv Radiol.
2011;22:1522–1530.e3.
8. Friedell ML, Nelson PR, Cheatham ML. Vena cava filter practices of a regional
vascular surgery society. Ann Vasc Surg. 2012;26:630–635.
9. Group PS. Eight-year follow-up of patients with permanent vena cava filters in
the prevention of pulmonary embolism: the PREPIC (Prevention du Risque
d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation.
2005;112:416–422.
10. Durack JC, Westphalen AC, Kekulawela S, Bhanu SB, Avrin DE, Gordon RL,
Kerlan RK. Perforation of the IVC: rule rather than exception after longer
indwelling times for the Gunther Tulip and Celect retrievable filters. Cardiovasc
Intervent Radiol. 2012;35:299–308.
11. Morales JP, Li X, Irony TZ, Ibrahim NG, Moynahan M, Cavanaugh KJ. Decision
analysis of retrievable inferior vena cava filters in patients without pulmonary
embolism. J Vasc Surg Venous Lymphat Disord. 2013;1:376–384.
12. US Food and Drug Administration. Removing retrievable inferior vena cava
filters: FDA safety communication. Available at: http://www.fda.gov/Medica
lDevices/Safety/AlertsandNotices/ucm396377.htm. Accessed April 15,
2016.
13. White RH, Geraghty EM, Brunson A, Murin S, Wun T, Spencer F, Romano PS.
High variation between hospitals in vena cava filter use for venous
thromboembolism. JAMA Intern Med. 2013;173:506–512.
14. Meltzer AJ, Graham A, Kim JH, Connolly PH, Karwowski JK, Bush HL, Meltzer
EC, Schneider DB. Clinical, demographic, and medicolegal factors associated
with geographic variation in inferior vena cava filter utilization: an interstate
analysis. Surgery. 2013;153:683–688.
15. Dossett LA, Adams RC, Cotton BA. Unwarranted national variation in the use
of prophylactic inferior vena cava filters after trauma: an analysis of the
National Trauma Databank. J Trauma. 2011;70:1066–1070; discussion 1070–
1071.
16. Brown JD, Talbert JC. Variation in the use of vena cava filters for venous
thromboembolism in Hospitals in Kentucky. JAMA Surg. 2016;151:984–986.
17. Brown JD, Talbert JC. Hospital variation and patient characteristics associated
with vena cava filter utilization. Med Care. 2017;55:31–36.
18. Siracuse JJ, Al Bazroon A, Gill HL, Meltzer AJ, Schneider DB, Parrack I, Jones
DW, Connolly PH. Risk factors of nonretrieval of retrievable inferior vena cava
filters. Ann Vasc Surg. 2015;29:318–321.
19. White RH, Garcia M, Sadeghi B, Tancredi DJ, Zrelak P, Cuny J, Sama P,
Gammon H, Schmaltz S, Romano PS. Evaluation of the predictive value of ICD-
9-CM coded administrative data for venous thromboembolism in the United
States. Thromb Res. 2010;126:61–67.
20. White RH, Zhou H, Kim J, Romano PS. A population-based study of the
effectiveness of inferior vena cava filter use among patients with venous
thromboembolism. Arch Intern Med. 2000;160:2033–2041.
21. Stein PD, Matta F, Alrifai A, Rahman A. Trends in case fatality rate in
pulmonary embolism according to stability and treatment. Thromb Res.
2012;130:841–846.
22. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD,
Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in
ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.
23. Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM,
Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of
chronic disease in primary care patients. J Clin Epidemiol. 2008;61:1234–1240.
24. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the
presence of competing risks. Circulation. 2016;133:601–609.
25. Mismetti P, Laporte S, Pellerin O, Ennezat PV, Couturaud F, Elias A, Falvo N,
Meneveau N, Quere I, Roy PM, Sanchez O, Schmidt J, Seinturier C, Sevestre
MA, Beregi JP, Tardy B, Lacroix P, Presles E, Leizorovicz A, Decousus H, Barral
FG, Meyer G; Group PS. Effect of a retrievable inferior vena cava filter plus
anticoagulation vs anticoagulation alone on risk of recurrent pulmonary
embolism: a randomized clinical trial. JAMA. 2015;313:1627–1635.
26. Lee JK, So YH, Choi YH, Park SS, Heo EY, Kim DK, Chung HS. Clinical course
and predictive factors for complication of inferior vena cava filters. Throm Res.
2014;133:538–543.
27. Caplin DM, Nikolic B, Kalva SP, Ganguli S, Saad WE, Zuckerman DA; SoIRSoP
Committee. Quality improvement guidelines for the performance of inferior
vena cava filter placement for the prevention of pulmonary embolism. J Vasc
Interv Radiol. 2011;22:1499–1506.
28. Rogers FB, Cipolle MD, Velmahos G, Rozycki G, Luchette FA. Practice
management guidelines for the prevention of venous thromboembolism in
trauma patients: the EAST practice management guidelines work group. J
Trauma. 2002;53:142–164.
29. Charlton-Ouw KM, Leake SS, Sola CN, Sandhu HK, Albarado R, Holcomb JB,
Miller CC, Safi HJ, Azizzadeh A. Technical and financial feasibility of an inferior
vena cava filter retrieval program at a level one trauma center. Ann Vasc Surg.
2015;29:84–89.
30. Davies R, Stanley J, Wickremesekera J, Khashram M. Retrieval rates of inferior
vena cava (IVC) filters: are we retrieving enough? N Z Med J. 2015;128:31–40.
31. Irwin E, Byrnes M, Schultz S, Chipman J, Beal A, Ahrendt M, Beilman G, Croston
JK. A systematic method for follow-up improves removal rates for retrievable
inferior vena cava filters in a trauma patient population. J Trauma.
2010;69:866–869.
32. Lynch FC. A method for following patients with retrievable inferior vena cava
filters: results and lessons learned from the first 1100 patients. J Vasc Interv
Radiol. 2011;22:1507–1512.
33. Minocha J, Idakoji I, Riaz A, Karp J, Gupta R, Chrisman HB, Salem R, Ryu RK,
Lewandowski RJ. Improving inferior vena cava filter retrieval rates: impact of a
dedicated inferior vena cava filter clinic. J Vasc Interv Radiol. 2010;21:1847–
1851.
34. Janne d’Othee B, Faintuch S, Reedy AW, Nickerson CF, Rosen MP. Retrievable
versus permanent caval filter procedures: when are they cost-effective for
interventional radiology? J Vasc Interv Radiol. 2008;19:384–392.
35. Sutphin PD, Reis SP, McKune A, Ravanzo M, Kalva SP, Pillai AK. Improving
inferior vena cava filter retrieval rates with the define, measure, analyze,
improve, control methodology. J Vasc Interv Radiol. 2015;26:491–498.e1.
36. Zhan C, Miller MR. Administrative data based patient safety research: a critical
review. Qual Saf Health Care. 2003;12(suppl 2):ii58–ii63.
37. Schneeweiss S, Avorn J. A review of uses of health care utilization databases
for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323–
337.
38. Aziz F, Spate K, Wong J, Aruny J, Sumpio B. Changing patterns in the use of
inferior vena cava filters: review of a single center experience. J Am Coll Surg.
2007;205:564–569.
39. Uberoi R, Tapping CR, Chalmers N, Allgar V. British Society of Interventional
Radiology (BSIR) Inferior Vena Cava (IVC) Filter Registry. Cardiovasc Intervent
Radiol. 2013;36:1548–1561.
40. Tao MJ, Montbriand JM, Eisenberg N, Sniderman KW, Roche-Nagle G.
Temporary inferior vena cava filter indications, retrieval rates, and follow-up
management at a multicenter tertiary care institution. J Vasc Surg.
2016;64:430–437.
41. Wang SL, Cha HH, Lin JR, Francis B, Elizabeth W, Martin P, Rajan S. Impact of
physician education and a dedicated inferior vena cava filter tracking system
on inferior vena cava filter use and retrieval rates across a large US health care
region. J Vasc Interv Radiol. 2016;27:740–748.
DOI: 10.1161/JAHA.117.006708 Journal of the American Heart Association 11






















Joshua D. Brown, Driss Raissi, Qiong Han, Val R. Adams and Jeffery C. Talbert
Vena Cava Filter Retrieval Rates and Factors Associated With Retrieval in a Large US Cohort
Online ISSN: 2047-9980 
Dallas, TX 75231
 is published by the American Heart Association, 7272 Greenville Avenue,Journal of the American Heart AssociationThe 
doi: 10.1161/JAHA.117.006708
2017;6:e006708; originally published September 4, 2017;J Am Heart Assoc. 
 http://jaha.ahajournals.org/content/6/9/e006708
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 
 for more information. http://jaha.ahajournals.orgAccess publication. Visit the Journal at 
 is an online only OpenJournal of the American Heart AssociationSubscriptions, Permissions, and Reprints: The 
 by guest on A
pril 23, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
